DelveInsight’s, “Septic Shock Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Septic Shock pipeline landscape. It covers the Septic Shock pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Septic Shock pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Septic Shock Pipeline. Dive into DelveInsight’s comprehensive report today! @ Septic Shock Pipeline Outlook

Key Takeaways from the Septic Shock Pipeline Report

• In June 2025, RWTH Aachen University announced aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival.
• DelveInsight’s Septic Shock Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Septic Shock treatment.
• The leading Septic Shock Companies such as Vivacelle Bio, Adrenomed, Inotrem, Northern Therapeutics, MYND Life Sciences and others.
• Promising Septic Shock Pipeline Therapies such as Adrecizumab, OctaplasLG, Ringer-Acetate, Iloprost, Isotonic saline, FE 202158 and others.

Stay ahead with the most recent pipeline outlook for Septic Shock. Get insights into clinical trials, emerging therapies, and leading companies with Septic Shock @ Septic Shock Treatment Drugs

Septic Shock Emerging Drugs Profile

• VBI-S: Vivacelle Bio

VBI-S is the first product in a clinical trial treating an aspect of septic shock to have 100% efficacy in phase IIA results and achieve all of its endpoints in the past 20 years. The Phase III VBI-S trial is also fully funded. VBI-1 utilizes the same platform technology to treat hemorrhagic shock. VBI-1 cleared to start phase II. VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without interfering with its production or essential cellular interactions. The drug is currently being investigated in the Phase III stage of development for the treatment of Septic Shock. 

• Adrecizumab: Adrenomed

Adrecizumab is a proprietary humanized monoclonal adrenomedulli-specific antibody. This targeted therapy inhibits excessive circulating sepsis-induced ADM and stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. Binding of the monoclonal antibody Adrecizumab to bioactive adrenomedullin (bio-ADM) in the blood traps and stabilizes the peptide-hormone, resulting in increased ADM concentrations within the blood vessels. Adrecizumab is currently in Phase II clinical developmental stage for the treatment of septic shock and acute heart failure. Adrecizumab treatment significantly improved all clinically relevant endpoints such as reduction of vascular leakage and vasopressor demand, stabilization of the circulation, normalization of fluid balance and kidney function. In preclinical septic shock models, Adrecizumab reduced the mortality by 50%. The drug is currently being investigated in the Phase II stage of development for the treatment of Septic Shock.

The Septic Shock Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Septic Shock with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Septic Shock Treatment.
• Septic Shock Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Septic Shock Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Septic Shock market

Explore groundbreaking therapies and clinical trials in the Septic Shock Pipeline. Access DelveInsight’s detailed report now! @ New Septic Shock Drugs

Septic Shock Companies

Vivacelle Bio, Adrenomed, Inotrem, Northern Therapeutics, MYND Life Sciences, and others.

Septic Shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Septic Shock Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Septic Shock Treatment. Learn about new drugs, Septic Shock Pipeline developments, and key companies with DelveInsight’s expert analysis @ Septic Shock Market Drivers and Barriers

Scope of the Septic Shock Pipeline Report

• Coverage- Global
• Septic Shock Companies- Vivacelle Bio, Adrenomed, Inotrem, Northern Therapeutics, MYND Life Sciences and others.
• Septic Shock Pipeline Therapies- Adrecizumab, OctaplasLG, Ringer-Acetate, Iloprost, Isotonic saline, FE 202158 and others.
• Septic Shock Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Septic Shock Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Septic Shock Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Septic Shock Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Septic Shock: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Septic Shock– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VBI-S: Vivacelle Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Adrecizumab: Adrenomed
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Septic Shock Key Companies
21. Septic Shock Key Products
22. Septic Shock- Unmet Needs
23. Septic Shock- Market Drivers and Barriers
24. Septic Shock- Future Perspectives and Conclusion
25. Septic Shock Analyst Views
26. Septic Shock Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/septic-shock-pipeline-insight